Vertex Pharmaceuticals, Inc.

Brad D Maxwell

Michael Aaron Brodney

John Patrick Maxwell

Dennis James Hurley

Kevin Michael Cottrell

Qing Tang

Upul Keerthi Bandarage

Jinwang Xu

Simon Giroux

Adam R Looker

Michael John Boyd

Ales Medek

Yi Shi

Ronald Lee Grey, Jr

Stefanie Roeper

Stephen Andrew Thomson

Lev Tyler Dewey Fanning

Kevin Gagnon

Mac Arthur Johnson, Jr

Peter D Jones

Philippe Marcel Nuhant

Diane M Boucher

Cavan McKeon Bligh

Setu Roday

Robert Francis Fimognari, Jr

Amy Beth Hall

Sarah Carol Hood

Sarathy Kesavan

Pedro Manuel Garcia Barrantes

Timothy Lewis Tapley

Rebecca Jane Swett

Rupa Sawant

Veronique Damagnez

Steven M Ronkin

Jingrong Cao

John E Cochran

Jon H Come

Michael P Clark

Suganthini S Nanthakumar

Kathy Stavropoulos

Haoxuan Wang

Muna Shrestha

Leslie A Dakin

Timothy J Senter

Kirk Overhoff

Steven David Stone

Mariam Zaky

Robert Daniel Giacometti

Samantha Guido

Jun Myun Ahn

Gabrielle Simone Fleming

Siying Liu

Marisa Sposato

Mei-Hsiu Lai

Akira Joseph Shimizu

Jessica Howard Olsen

Samantha Angle

Elena Dolgikh

Edward H Ruediger

Shoshana L Posy

Daniel H Deon

Jacques Banville

Eldon Scott Priestley

Hardwin O'Dowd

Marc Gagnon

Michael Waldo

Pancras C Wong

Julia Guy

Mettachit Navamal

Joshua Kennedy Hussey

Mary Elizabeth Eccles

Hardwin O′dowd

Roger Remillard

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

Inhibitors of APOL1 and methods of using same

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Modulators of alpha-1 antitrypsin

Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).

Growing community of inventors

Holliston, MA, United States of America

Brad D Maxwell